AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the underwriter of its previously announced bought deal offering of common stock has partially exercised its option to purchase an additional 7,030,927 shares of common stock at a price to the public of $1.60 per share. After giving effect to the exercise of option to purchase additional shares, the total number of shares sold by AIkido in the bought deal offering increased to 53,905,927 shares and gross proceeds increased to approximately $86.2 million, before deducting underwriting discounts and commissions and other offering expenses.
H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
The shares of common stock described above were offered pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on June 18, 2020. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at placements@hcwco.com or by telephone at 646-975-6996.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 3/5/2021
Views: 930
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 3/3/2021
Views: 910
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 3/1/2021
Views: 940
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 3/1/2021
Views: 1350
Meet Aikido Pharma Inc’s Board of Directors
Released On: 2/28/2021
Views: 958
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 2/23/2021
Views: 979
Artificial Intelligence Is Optimizing Drug Development
Released On: 2/22/2021
Views: 1004
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 2/20/2021
Views: 886
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 2/19/2021
Views: 1044
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 2/16/2021
Views: 1138
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 2/16/2021
Views: 1091
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 2/16/2021
Views: 1229
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 2/15/2021
Views: 887
Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19
Released On: 2/10/2021
Views: 801
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 2/9/2021
Views: 1401
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 2/5/2021
Views: 975
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 2/3/2021
Views: 1852
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 2/3/2021
Views: 1075